LATIFY Chain of Custody
Production Engine OutputResponder
Score0.114
Rank#1042
Non-Responder
Score0.91
Rank#42
Delta Fit-0.1Production cosine_sim()
(CrisPRO engine: Predicted Futility 90%; Observed HR 0.90; P=0.287; receipt: latify_curl_receipts.json)
Retroactive (2023-2024)
9/9RETSelpercatinib
0.3526
IDH1Vorasidenib
0.3525
IDH2Vorasidenib
0.3549
PIK3CAInavolisib triple
0.3533
ERBB2Zanidatamab
0.3526
KMT2ARevumenib
0.3529
FGFR3Erdafitinib
0.3527
NRG1Zenocutuzumab
0.3525
FOLR1Mirvetuximab (ELAHERE)
0.3527
Prospective (Feb 2026)
ImmutableHER3Patritumab Dx (HER3-DXd)
APPROVETROP2Dato-DXd
APPROVEB7H4AZD8205
PENDINGCEACAM5Tusamitamab Ravtansine
FAILUREKRAS G12CAdagrasib+Cetuximab
N/AROS1Zidesamtinib (NVL-520)
APPROVETHE $300M ROW
CEACAM5 is the second LATIFY. Both have HIGH Target-Lock (real targets) and both failed from unselected/insufficiently gated enrollment.